

Supplementary data

Table S1. PD-L1 expression in tumor cells and tumor-infiltrating immune cells in paired HCC tissues before and after sorafenib treatment.

IHC score ^a	Before sorafenib	After sorafenib
	(Tissue-1)	(Tissue-2)
	N (%)	N (%)
Total	23 (100.0)	23 (100.0)
Tumor-infiltrating immune cells		
0	11 (47.8)	5 (21.7)
1	5 (21.7)	5 (21.7)
2	5 (21.7)	2 (8.7)
3	2 (8.7)	11 (47.8)
Tumor cells		
0	19 (82.6)	14 (60.7)
1	2 (8.7)	5 (21.7)
2	0 (0)	0 (0)
3	2 (8.7)	4 (17.4)

^aPD-L1 expression was scored as IHC 0, 1, 2, or 3 if <1%, ≥1% but <5%, ≥5% but <10%, or ≥10% of cells were PD-L1 positive, respectively. Abbreviations: IHC =

immunohistochemistry; HCC = hepatocellular carcinoma; PD-L1 = programmed death-ligand 1.